Loading…
Loading…
EQUITY / NASDAQ · XNCM
Decoy Therapeutics Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.97 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 1.97 USD · Volume 238,050
62 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Revenue | 227,629 USD | 0 USD | — |
| Operating profit | -2,631,021 USD | -965,565 USD | — |
| Net income | -2,373,800 USD | -957,825 USD | — |
| Cash and cash equivalents | 8,289,108 USD | — | — |
| Total liabilities | 4,680,254 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 8,289,108 USD | — | — | 10,709,937 USD | 10,709,937 USD | 4,809,680 USD | — | — |
| Net incomeIncome statement | -2,373,800 USD | -4,598,428 USD | -2,224,628 USD | — | -12,518,480 USD | -873,467 USD | -3,540,825 USD | -957,825 USD |
| Operating profitIncome statement | -2,631,021 USD | -4,914,760 USD | — | — | -12,613,952 USD | -895,130 USD | -3,579,390 USD | -965,565 USD |
| RevenueIncome statement | 227,629 USD | 227,629 USD | — | — | — | — | — | 0 USD |
| Total assetsBalance sheet | 9,001,160 USD | — | — | 11,056,707 USD | 11,056,707 USD | 6,097,032 USD | — | — |
| Total equityBalance sheet | 4,320,906 USD | — | 3,877,385 USD | 5,888,969 USD | 5,888,969 USD | 4,248,065 USD | — | -829,724 USD |
| Total liabilitiesBalance sheet | 4,680,254 USD | — | — | 5,167,738 USD | 5,167,738 USD | 1,848,967 USD | — | — |
| Financing cash flowCash flow statement | — | 3,162,943 USD | — | — | 12,337,862 USD | — | 6,265,852 USD | — |
| Investing cash flowCash flow statement | — | -42,424 USD | — | — | 764,735 USD | — | -200,000 USD | — |
| Operating cash flowCash flow statement | — | -5,541,348 USD | — | — | -4,827,188 USD | — | -3,690,700 USD | — |
| Capital expendituresCash flow statement | — | — | — | — | 577,000 USD | — | — | — |
| Report source | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 03/31/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/12/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.